Last reviewed · How we verify
Premixed insulin
Premixed insulin combines rapid-acting and intermediate-acting insulin to provide both immediate and sustained blood glucose control.
Premixed insulin combines rapid-acting and intermediate-acting insulin to provide both immediate and sustained blood glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Premixed insulin |
|---|---|
| Also known as | Novolog Mix 70/30, Biphasic Aspart 30 |
| Sponsor | Peking University People's Hospital |
| Drug class | Insulin combination therapy |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Premixed insulin formulations contain a fixed ratio of short-acting (or rapid-acting) insulin and intermediate-acting insulin in a single injection. The rapid-acting component begins working within minutes to control postprandial (after-meal) glucose spikes, while the intermediate-acting component provides basal insulin coverage over several hours. This combination reduces the need for multiple daily injections while maintaining glycemic control.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (PHASE2)
- Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents (PHASE4)
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes (PHASE1, PHASE2)
- A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus (PHASE4)
- Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus (PHASE4)
- Hybrid Method Between Low-ratio Premixed Insulin and Short Acting Insulin in Fasting Type 2 Diabetic Patients in Ramadan
- A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |